Expert Shares Insight on Utility of Immunotherapy and Targeted Agents Across NSCLC
Published: Tuesday, Mar 24, 2020
Gregory A. Otterson, MD
With the influx of approved immunotherapy and targeted therapy agents available for patients with non–small cell lung cancer (NSCLC), understanding when to utilize one treatment regimen over the other is a key component of optimal care, said Gregory A. Otterson, MD.
... to read the full story